Clinical trials
Vaccination clinical trials
Below are recruiting vaccination clinical trials, each written for real people, not researchers. We’re tracking 598 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06799026RecruitingPhase 1
Vaccine plus elranatamab for advanced multiple myeloma
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
Boston, MassachusettsAges 18 years+ - NCT06841913RecruitingPhase 4
Woodsmoke, flu, and your nasal immune response
This study tests how breathing woodsmoke affects your nose's ability to fight off the flu virus. You will be exposed to woodsmoke and then given a live flu vaccine to see how your immune system responds.
Chapel Hill, North CarolinaAges 18–49 - NCT06862102Recruiting
Multiple HPV Infections and Cervical Lesion Risk
This study looks at how having multiple types of HPV virus affects the development of abnormal cervical cells (called CIN). It may help doctors understand why some people are more at risk and could lead to better prevention.
Pavia, PaviaAges 18 years+ - NCT06862453RecruitingPhase 1
Safety of a new malaria vaccine in healthy adults
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
TübingenAges 18–45 - NCT06868433RecruitingPhase 1
TMV vaccine alone or with pembrolizumab for advanced HNSCC
This trial tests a vaccine made from your own tumor to help your immune system fight head and neck cancer that has returned or spread. It is given alone or with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors or slow progression.
Atlanta, GeorgiaAges 18 years+ - NCT06891417RecruitingPhase 1/Phase 2
Chlamydia mRNA vaccine study for adults 18-29
This study tests a new mRNA vaccine designed to prevent chlamydia infection. It is for adults aged 18 to 29 who have a higher risk of getting chlamydia.
Bruce, Australian Capital TerritoryAges 18–29 - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+ - NCT06955728RecruitingPhase 3
RSV vaccine in pregnancy to protect babies
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
Kintampo, Bono EastAges 14–55 - NCT06958198RecruitingPhase 1
Testing a new multi-stage malaria vaccine in adults and children
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
Siglé, Boulkiemdé ProvinceAges 5 months–35 years - NCT06980155RecruitingEarly Phase 1
Personalized vaccine with or without toripalimab to prevent AML relapse
This trial tests a personalized cancer vaccine, alone or with an immunotherapy drug called toripalimab, to help keep acute myeloid leukemia (AML) in remission. It is for people who have finished initial treatment, are in remission, but still have some leukemia cells remaining (MRD positive) and have a specific NPM1 gene mutation.
ShanghaiAges 18 years+ - NCT07000708Recruiting
Vaccination, time-restricted eating, aging, and lifestyle study
This trial tests whether time-restricted eating (eating only during an 8-hour window each day) can improve how well your body responds to flu and COVID-19 vaccines. It is designed for older adults who want to see if this simple eating pattern boosts their immune system.
BerlinAges 60–85 - NCT07003984RecruitingPhase 3
Chikungunya vaccine study for children
This study tests a vaccine for chikungunya virus in children aged 1 to 12. It aims to see if the vaccine is safe and helps the body build protection against the virus.
Fountain Valley, CaliforniaAges 1–11 - NCT07004244RecruitingPhase 1
KRAS vaccine study for people with KRAS-mutated cancers
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
Chengdu, SichuanAges 18 years+ - NCT07036159RecruitingPhase 2
Malaria vaccine safety study for children ages 5 months to 5 years
This trial tests a new malaria vaccine in healthy children. It aims to see if the vaccine is safe and how well it works in children who have had their regular childhood shots.
KigaliAges 5 months–5 years - NCT07038837RecruitingPhase 4
Comparing two ways to give the R21 malaria vaccine in Chad
This study tests two ways of giving the R21 malaria vaccine to children in Chad during the rainy season. One way follows the routine vaccination schedule, and the other gives the vaccine at the same time as seasonal malaria prevention medication.
Moïssala, Mandoul RegionAges 6 months–4.9 years - NCT07049159RecruitingPhase 2
Testing a new oral vaccine to prevent shigella and ETEC infection
This trial tests an oral vaccine designed to protect against two common causes of severe diarrhea: shigella and ETEC bacteria. Healthy adults aged 18 to 50 will receive the vaccine and later be exposed to the bacteria to see if it works.
Baltimore, MarylandAges 18–50 - NCT07077356RecruitingPhase 1
mRNA vaccine for liver cancer patients awaiting transplant
This trial tests an mRNA vaccine for people with liver cancer who are waiting for a liver transplant. The vaccine is given to help control the cancer while they wait.
ChengduAges 18 years+ - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07195032RecruitingPhase 4
MMR vaccine safety in kids after heart transplant
This trial tests whether the MMR (measles, mumps, rubella) vaccine is safe and works well for children who have had a heart transplant. It may help protect you from these diseases if you haven't had the vaccine or no longer have immunity.
Kansas City, MissouriAges 1–17 - NCT07203755RecruitingPhase 1
Combination vaccine for whooping cough, Hib, and meningitis
This trial tests a new combination vaccine that protects against whooping cough, Haemophilus influenzae type b (a cause of meningitis and pneumonia), and several types of meningococcal disease (a cause of meningitis and bloodstream infections). It may help reduce the number of shots needed for children.
Shangqiu, HenanAges 2 months–6 years - NCT07211152RecruitingPhase 3
Flu vaccine study for pregnant women
This study tests a flu shot designed for pregnant women to see if it is safe and effective. It may help protect you and your baby from the flu during pregnancy.
Mandaluyong, National Capital RegionAges 18–39 - NCT07216430RecruitingPhase 2
Safety and efficacy of a pneumococcal vaccine in young kids
This study tests a new pneumococcal vaccine (wSp) in young children who have already had 3 doses of a standard pneumococcal shot. It aims to see if the new vaccine is safe and works well to protect against serious infections.
Pittsford, New YorkAges 5 months–7 months - NCT06741072RecruitingPhase 1
Vaccine to prevent EBV-related cancer in transplant patients
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Columbus, OhioAges 18–65 - NCT07259252Recruiting
Flu vaccine study for heart attack or unstable angina patients
This study tests whether getting a flu vaccine helps people who recently had a heart attack or unstable angina (acute coronary syndrome). It looks at whether vaccination can reduce future heart problems.
Wuhan, HubeiAges 18–80
Hear when a new Vaccination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for vaccination?
- Yes. Clin2 currently lists 598 recruiting vaccination studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vaccination trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vaccination trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.